To report a case of obstetrical disseminated intravascular coagulation and discuss the treatment strategy of such cases. The clinical data and treatment process of the patient with cardiac arrest and disseminated intravascular coagulation after amniotic fluid embolism was analyzed, and the related literature was reviewed. Female, 36 years old, primigravida, was admitted to the hospital for delivery because of "amenorrhea for more than 9 months, lower abdominal pain for 14 hours with a small amount of vaginal bleeding for 2 hours", amniotic fluid embolism occurred after delivery, then cardiac arrest and DIC happened, which led to a large amount of blood loss, through the treatment methods of active circulatory and respiratory support, surgical interventions for two times, transfusion of erythrocytes, plasma, and cold precipitation, fibrinogen and other blood product for substitution, and early antifibrinolytic, the patient's life was successfully saved without irreversible organ function damage. For patients with obstetrical disseminated intravascular coagulation, in addition to treating the primary disease, it is necessary to correct coagulation function by component transfuse and antifibrinolytic as appropriate to improve the prognosis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3760/cma.j.cn121090-20241129-00498 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and safety of antithrombin or recombinant human thrombomodulin in the treatment of disseminated intravascular coagulation: A systematic review and meta-analysis.
Thromb Res
March 2025
Department of Critical Care Medicine, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai 200120, China. Electronic address:
Objective: Multiple organ damage is a hallmark of the highly lethal condition known as disseminated intravascular coagulation (DIC). The efficacy and safety of recombinant human soluble thrombomodulin (rhTM) and antithrombin (AT) in DIC is still debatable. Therefore, we used a fixed-effects model to conduct a comprehensive evaluation and meta-analysis to examine the safety and efficacy of AT or rhTM administration for treating DIC.
View Article and Find Full Text PDFRapid Development of Unclassified Myeloid Lineage Acute Leukaemia With Trisomy 6 and U2AF1 Mutation.
J Cell Mol Med
March 2025
Faculty of Medicine, Division of Laboratory Medicine, Medical University of Gdansk, Gdansk, Poland.
We present a case of acute clonal bone marrow 98% infiltration of atypical myeloid cells with borderline hypogranular/agranular promyelocytes/myelocytes and occasional blast cells maturity, which also formed extramedullary tumours in the chest wall, with isolated trisomy of chromosome 6 and pathogenic variant U2AF1 (S34F) that escapes established acute myeloid leukaemia (AML) diagnostic criteria according to the World Health Organization (WHO) classification. Following standard daunorubicin and cytarabine induction therapy, the disease progressed with the appearance of a previously undetected clone of leukaemic cells with a distinct immunophenotype demonstrating monocytoid differentiation and clonal evolution to a hypo-tetraploid karyotype with an average number of 84 chromosomes and new pathogenic NRAS and ZRSR2 mutations. The patient reactivated refractory disseminated intravascular coagulation (DIC) leading to a progressive supratentorial hematoma and finally cardiac arrest.
View Article and Find Full Text PDF[Analysis of risk factors for early death in hyperleukocytic acute leukemia].
Zhonghua Xue Ye Xue Za Zhi
January 2025
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China Tianjin Institutes of Health Science, Tianjin 301600, China.
This study analyzed the clinical characteristics and early mortality risk factors in patients with hyperleukocytic acute leukemia (HAL) to provide a basis for predicting early prognosis. Data were retrospectively collected from 211 patients with primary HAL who visited the Emergency Center of the Hematology Hospital, Chinese Academy of Medical Sciences, between July 1, 2019 and November 30, 2021. The value of each indicator in early risk stratification and prognosis was analyzed.
View Article and Find Full Text PDF[Clinical characteristics and prognostic analysis of newly diagnosed acute myeloid leukemia with critical illness].
Zhonghua Xue Ye Xue Za Zhi
January 2025
National Clinical Research Center for Hematologic Diseases, the First Affiliated Hospital of Soochow University, Department of Hematology, Intensive Care Unit, Jiangsu Institute of Hematology, Suzhou 215006, China.
This study retrospectively analyzed the clinical characteristics of patients newly diagnosed with acute myeloid leukemia (AML) who were admitted to the hematology intensive care unit (HCU) with critical illness. It also examined factors associated with critical illness and early mortality in these patients. Clinical data were collected from 91 newly diagnosed AML patients admitted to the HCU of the Department of Hematology, First Affiliated Hospital of Soochow University, from October 2020 to 2024.
View Article and Find Full Text PDFAdverse events reporting of edaravone: a real-world analysis from FAERS database.
Sci Rep
March 2025
Department of Pharmacy, Pingtan Comprehensive Experimental Area Hospital, Pingtan Comprehensive Experimental Area, Pingtan, 350400, People's Republic of China.
For individuals with amyotrophic lateral sclerosis (ALS), intravenous edaravone is approved as a disease-modifying medication; yet, there have been many reports of adverse events (AEs). We examined the AEs associated with edaravone in this study using actual data from the FDA's (Food and Drug Administration) adverse event reporting system (FAERS). By extracting large-scale data from the FAERS database, this study used the signals of edaravone-associated AEs were quantified using the multiitem gamma Poisson shrinker (MGPS) method based on disproportionality, the Bayesian confidence propagation neural network (BCPNN), the reporting odds ratio (ROR), and the proportional reporting ratio (PRR).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!